Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial

Article Cardiac & Cardiovascular Systems

Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin

Muthiah Vaduganathan et al.

Summary: This study found that canagliflozin, an SGLT2 inhibitor, delays the increase of hs-cTnT and sST2 and reduces the occurrence of heart failure and kidney events. High levels of hs-cTnT and sST2, along with other cardiovascular biomarkers, can predict cardiovascular and kidney outcomes and may influence the treatment effects of canagliflozin.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Gliflozins in the Management of Cardiovascular Disease

Eugene Braunwald

Summary: Gliflozins, a type of medication used to treat type 2 diabetes, not only lowers blood glucose levels but also improves cardiac and renal function.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis

Darren K. McGuire et al.

Summary: SGLT2 inhibitors were found to reduce the risk of major adverse CV events and showed significant heterogeneity in associations with CV death. The most consistent benefit of this class of drugs was a reduction in risk for heart failure and kidney outcomes, with heart failure risk reduction being the most consistent observation across the trials.

JAMA CARDIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Deepak L. Bhatt et al.

Summary: The trial involving 10,584 patients with diabetes and chronic kidney disease showed that sotagliflozin resulted in fewer deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure compared to placebo. However, there were adverse events such as diarrhea, mycotic infections, and diabetic ketoacidosis associated with sotagliflozin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems